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Abstract
        Risk evaluation and prognostic stratification based upon clini-
cal and radiological findings and new cardiac biomarkers, such 
as natriuretic peptides (NP) and troponins, represent key points 
in modern management of acute pulmonary embolism (PE). Lit-
erature  evidence  shows  that  normotensive  PE  with  right  heart 
dysfunction (RHD), defined as submassive PE,  has poorer prog-
nosis when compared to normotensive PE without RHD, defined 
as non-massive PE; thus whether submassive PE should be man-
aged more aggressively and with closer monitoring represents the 
crucial question about acute PE treatment. Although the answer 
is yet unclear, the most recent guidelines address to thrombolysis 
as treatment choice in selected high risk patients with submassive 
PE. Guidelines also clarify the  indications for  unfractioned and 
low molecular weight heparins and fondaparinux. Therefore, in the 
present article, the authors focus on modern risk-based therapeutic 
guidelines of acute PE.
Keywords:  Pulmonary  embolism;  Treatment;  Prognosis; 
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Introduction
  Pulmonary  embolism  (PE)  is  a  frequent  disorder  in 
clinical practice with a hospital incidence of 0.4% of all 
admissions [1]. Mortality rate varies according to clinical 
presentation, in fact, it is about 2% in patients who appear 
normotensive without right heart compromise, it increases 
to 10-15% in normotensive patients with right heart compro-
mise, and reaches around 30% in patients who present with 
cardiogenic shock and 70% in patients who present with car-
diac arrest [2]. Treatment is usually effective when properly 
and quickly started; it should be kept in mind that about 10% 
of patients died within the first hour from onset of symptoms 
[2]. Thus early diagnosis, quick and appropriate treatment 
customized according to strict clinical and prognostic evalu-
ation of the patient, are crucial moments in the modern thera-
peutic approach to this disease. 
   Since many years, thrombolysis was recognized to find 
indications in haemodinamically unstable patients with PE, 
in other words, in patients with shock (systolic blood pres-
sure, SBP, under 90 mm Hg). Up to now, the big question on 
therapy has been represented whether or not thrombolysis 
was also indicated in normotensive patients with evidence 
of right heart dysfunction (RHD) who have a significantly 
worse prognosis than normotensive patients without RHD. 
In  the  MAPPET  III  Study  (Management  Strategies  And 
Prognosis of Pulmonary Embolism Trial-3), Konstantinides 
et al. had shown that, although in normotensive patients with 
RHD (condition defined as submassive-intermediate risk PE, 
see later), treatment with thrombolysis reduced mortality in 
a non-significant percentage, 3.4% in patients treated with 
unfractionated heparin (UFH) vs 2.2% in patients thrombo-
lysed, p = ns, compared with more bleeding events in pa-
tients treated with thrombolysis; at the same time; thrombo-
lytic treatment, added  in patients initially treated with UFH 
with subsequent evolution toward hemodynamic instability 
(rescue treatment), clearly and significantly reduced mortal-
ity compared to patients not undergoing this treatment in 
the event of deteriorating hemodynamics (mortality 10.2 vs. 
24.6% respectively, p < 0.05) [3]. Therefore, this trial had 
established the role of thrombolysis as rescue therapy in nor-
motensive patients with RHD and initially treated with UFH 
that evolves towards hemodynamic instability, but throm-
bolysis was not recommended by the VII Edition guidelines 
of American College of Chest Physicians (ACCP) in nor-
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motensive patients with RHD [4]. The increase of scientific 
evidence in favor of increased risk of mortality in patients 
with RHD without shock or hypotension at presentation and 
especially the considerable amount of evidence relating to 
the role of some prognostic biomarkers recently introduced 
(troponins and natriuretic peptides) complementary to the 
diagnostic imaging (echocardiography and computer tomog-
raphy pulmonary angiography, CTPA) resulted in the de-
velopment of new therapeutic guidelines of PE in the acute 
phase, based on the estimation of clinical risk and prognostic 
stratification much recently published (European Society of 
Cardiology, ESC, August 2008, ACCP, VIII Edition, June 
2008), which will be discussed in this article [5, 6].
 
 
Haemodinamic consequences of PE 
 The  extension  of  obstructed  pulmonary  arterial  bed, 
the pre-existence of cardio-pulmonary disease and response 
to the release of vasoactive substances determined by local 
thrombus influence the pathophysiological response in acute 
PE [2, 7]. The obstruction, caused by mechanical thrombus 
associated with pulmonary vasoconstriction determined by 
the release of vasoactive substances and hypoxia, leads to 
an increase of pulmonary vascular resistances and after-load 
of the right ventricle. This increase may result in right heart 
dilation,  myocardial  ischemia  and  hypokinesia,  trcuspidal 
regurgitation or insufficiency, and finally right ventricular 
failure. In some patients, a rapid deterioration in progres-
sive systemic arterial hypotension, cardiogenic shock and 
cardiac arrest may occur. Approximately 5-10% of patients 
with normal blood pressure at presentation have a rapid de-
terioration in the early stages of the hospital admission, and 
this event is due to the recurrence of embolisation or to the 
acute dysfunction of the right ventricle [2, 7]. The hemody-
namic consequences of PE are summarized in Figure 1. The 
respiratory consequences of PE are represented mainly by 
mismatch ventilation/perfusion (pulmonary areas ventilated 
but not perfused), increased of total dead space and right-left 
shunts [2, 7]. 
 
 
Old and new clinical classification of PE 
  PE  is  classically  divided  into  massive  form  when 
manifested by cardiac arrest, cardiogenic shock or arterial 
hypotension (haemodynamically unstable form) form, sub-
massive (PE with RHD but without hemodynamic instabil-
Figure 1.  Pathophysiology of hemodynamic instability due to PE. RV, Right Ventricle; LV, Left Ventricle; BNP, Brain Natriuretic 
Peptide; NT-proBNP, AminoTerminal-proBrain Natriuretic Peptide.
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ity) and non-massive form (PE without RHD and without 
hemodynamic instability, usually caused by an obstruction 
of pulmonary arterial bed < 30%) [2, 6, 8, 9]. 
  Most recently, European Society of Cardiology (ESC) 
proposed to divide the clinical pictures of PE on the basis of 
clinical risk and prognosis; it follows that PE is divided into 
high risk (previous massive PE, mortality > 15% in the acute 
phase) and not high risk forms [5]. The latter is divided into 
intermediate risk form (previous sub-massive PE, mortality 
3-15%) and low-risk form (previous non-massive PE, mor-
tality < 3%). Table 1 summarizes the ESC classification of 
PE. 
 
 
Risk assessment and prognostic stratification
  Patients over 75 years, bed rest over four days, cancer, 
chronic obstructive pulmonary disease, heart failure, kidney 
failure, tachycardia and syncope are all clinical and comor-
bidity indicators of poor prognosis in acute PE [10, 11]. 
  However the most important negative prognostic indi-
cator in patients with PE is shock at presentation or during 
the acute phase of illness [2]. The ESC defines high risk PE 
as when it occurs with shock or arterial hypotension (SBP < 
90 mm Hg); the relief of RHD and elevated biomarkers is 
not necessary to define the high risk [5]. It was recently in-
troduced a parameter defined as shock index (ratio between 
heart rate in beats per minute and SBP in mm Hg), it is easy 
to apply in clinical practice. A value of shock index > 1 cor-
relates with the echocardiographic presence of RHD and in-
creased pulmonary arterial systolic pressure (sPAP) and it is 
associated with increased hospital  and thirty-days mortality 
[12, 13]. 
  Pulmonary Embolism Severity Index (PESI) is a score 
 
ATS 1999, ESC 2000, BTS 2003, ACEP 2003, ACCP 2004, ACCP 2008
•	 MASSIVE (cardiac arrest,  shock, hypotension)
•	 SUB-MASSIVE (normotensive PE with RHD )
•	 NON MASSIVE (normotensive PE without RHD)
ESC 2008
•	 HIGH RISK (cardiac arrest, shock, hypotension)
•	 NON HIGH RISK
•	 INTERMEDIATE RISK (normotensive PE with RHD and/or high BNP and/or high troponins)
•	 LOW RISK (normotensive PE without RHD and low BNP and low troponins)
Table 1.  Clinical classification of PE
ATS, American Thoracic Society; ESC, European Society of Cardiology; BTS, British Thoracic Society; ACEP; American College 
of Emergency Physicians; ACCP; American College of Chest Physicians; RHD; right heart dysfunction.
Risk 
(mortality in acute 
phase %)
Shock/hypotension 
Echocardiographic and 
biomarkers findings of 
RHD 
(­  ↑ BNP or NTpro-BNP) 
Findings of myocardial 
injury: ↑ troponin I or T
High
(15%)
Present Present* Present* 
Intermediate
(3 - 15%)
Absent
Absent
Absent
Present
Absent
Present
present 
Present 
Absent 
Low
(< 3%)
Absent Absent Absent 
Table 2. ESC criteria for identifying the prognostic risk of PE
*generally present but not necessary to define high risk
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that identifies 5 classes with a growing risk of mortality ac-
cording to a strictly clinical parameters [14]. The patients in 
class I - II (low risk, mortality ≤ 1.2%) may receive less ag-
gressive therapy (subcutaneous low molecular weight hepa-
rins, LMWH, or fondaparinux and vitamin K antagonists) 
and they could be discharged from hospital more quickly 
or even could receive home treatment, whereas patients in 
class III - IV (mortality rate 4.8, 13.6, 25%, respectively) 
should receive more aggressive treatment and close moni-
toring [14]. 
 The electrocardiographic findings more indicative of 
negative prognosis in acute PE are the presence and number 
of negative T waves on precordial leads [15]. The tradition-
al parameters offered by arterial blood gas analysis do not 
seem to offer advantages in terms of prognosis. 
  Trans-thoracic echocardiography is the golden diag-
nostic  standard  for  identifying  RHD  [16,  17].  The  main 
echocardiographic findings of RHD are represented by hy-
pokinesia of right ventricle (mild, moderate, severe), dila-
tation of right ventricle (four chambers end-diastolic right 
ventricle/left ventricle diameter ratio > 1), and  findings of 
pulmonary arterial hypertension [17]. The presence of RHD 
at echocardiography is related to a negative prognosis both 
in shock patients and in normotensive patients [11, 17]. 
  About 80% of patients with PE are normotensive at 
presentation; from one third to half of normotensive patients 
have  echocardiographic  RHD  [10,  18].  In  normotensive 
patients without RHD the range of hospital mortality is 0 
- 9.6%, while in patients with RHD is 11.8 - 23% [19]. Nor-
motensive patients with echocardiographic RHD have also 
reduced survival of 30 days (mortality increased to 17%) 
compared to patients without RHD [18]. The presence of 
RHD at presentation correlates also with poor pulmonary 
thrombi dissolution at six months and with the greatest inci-
dence of recurrence of venous thromboembolic events [20]. 
   Computer tomography pulmonary angiography (CTPA) 
has become the golden standard diagnostic method for PE. It 
may give also prognostic information. By using information 
derived from CTPA imaging it is possible to consider 3 indi-
ces of PE severity: the CTPE index (Computer Tomography 
Pulmonary Embolism index), which assesses the degree of 
obstruction and the number of pulmonary arteries affected 
by PE [21]; the right ventricle/left ventricle diameter ratio 
assessed by CTPA, when increased more than 1, it seems to 
correlate with a negative prognosis [22]; and a new index 
much recently proposed by Ghanima et al, which assesses 
the degree of proximality of pulmonary arteries involvement 
in respect to main pulmonary artery [23]. All these indexes 
correlate with severity and prognosis of PE, but in literature 
there are no consistent data for their use as a prognostic tool 
in routine clinical practice. 
  Among the biomarkers used for prognostic stratifica-
tion of PE, with proven effectiveness are the results of tropo-
nins assay (I and T) and natriuretic peptides (brain natriuretic 
peptide or its terminal portion, BNP and NT-proBNP respec-
tively). The increase of troponins indicates myocardial dam-
age and the expression of microinfarcts of right ventricular 
wall, while the natriuretic peptides are indices of RHD and 
their increase is attributable to stress of right ventricular wall 
[5]. The increase in these biomarkers was related to echocar-
diographic and CTPA data of RHD, it has negative predictive 
Figure 2. Summary of PE treatment according to modern guidelines. RHD, right heart dysfunction; BNP, brain natriuretic 
peptide; IV, intravenous; SC, subcutaneous.
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value [24]. Recent meta-analysis confirms that the increase 
in troponin I and T and natriuretic peptides is predictive of 
adverse prognosis in terms of mortality and morbidity in 
the acute phase of PE [25-27]. Hence, the rational basis for 
the introduction of these biomarkers is complementary to 
echocardiographic data in the evaluation of the clinical se-
verity and prognostic stratification of PE made by ESC [5]. 
Table 2 summarizes the classes of risks suggested by ESC 
together with the parameters used to define them. It is pos-
sible to notice that the intermediate class at risk, for which 
therapy is most debated, provides for the possibility of three 
combinations arising from the presence or absence of RHD 
at  echocardiography,  increased  natriuretic  peptides  and/or 
troponins. 
 Finally other biomarkers evaluated in terms of prog-
nosis are D-dimer, its values seem to be correlated linearly 
with the commitment thrombotic proximal pulmonary ar-
tery and the clinical severity of PE [28], which, however, 
being very sensitive and relatively little specific, is unlike-
ly as considerable prognostic index. The hearty type fatty 
acid  binding  proteins  (htFABP)  whose  growth  seems  to 
correlate better than BNP and troponins with the progno-
sis of PE in the acute phase [29], but at the moment they 
are  not  widely  disseminated  in  the  hospital  laboratories.   
 
 
Modern guidelines for antithrombotic therapy 
in the acute phase of PE 
  Modern  treatment  guidelines  proposed  by  ESC  and 
ACCP indicate that the treatment of acute PE is based on 
the clinical risk and prognostic stratification, it is based on 
pharmacological and non-pharmacological strategies. Figure 
2 summarizes the antithrombotic treatment of PE depending 
on the category of risk. 
 First of all, patients with high probability of clinical PE 
should receive an intravenous bolus of UFH, less than con-
traindications, when they undergo inspection for confirma-
tion. 
 In patients with massive/high-risk PE and hemodynam-
ically unstable, thrombolytic therapy has shown to improve 
more quickly hemodynamic compromise, while it is uncer-
tain about long-term outcomes [5, 6]. Among the possible 
thrombolytic agents, streptokinasis, urokinasis and recom-
binant  tissue  plasminogen  activator  (rtPA,  alteplase),  the 
last one is preferable. Schemes of thrombolytic therapy with 
infusions of short duration (≤ 2 h) are suggested compared 
to longer infusions (12 - 24 h) that do not have beneficial 
effects on hemodynamics and that are burdened by higher 
bleeding complications. The rtPA is administered by bolus 
of 10 mg IV, followed by 2 hours in a dose determined by 
body weight; it must not be exceeded the total dose of 100 
mg. In cases of extreme severity, it can be administered by 
dose of 0.6 mg/kg of bolus rtPA IV in rapid 5 - 15 minutes, 
but not exceeding the maximum dose of 50 mg IV. It should 
be noted that during the infusion of rtPA, The UFH infusion 
should be discontinued and then resumed after the infusion 
of thrombolytic [5, 6]. 
 
Absolute 
•  Haemorragic stroke or stroke of unknown origin at any time 
•  Ischemic stroke within six months 
•  Central nervous system damage or cancer 
•  Recent major trauma/surgery/head injury within three weeks 
•  Gastrointestinal bleeding within last months 
•  Known bleeding 
Relative
•  Age over 85 years 
•  Transient ischemic attacks in the previous six months 
•  Vitamin K antagonists treatment
•  Traumatic cardio-pulmonary resuscitation 
•  Non compressible punctures within 30 days 
•  Refractary hypertension (systolic blood pressure > 180 mm Hg)
•  Pregnancy or within one week post-partum 
•  Infective endocarditis 
•  Advanced liver disease 
•  Active peptic ulcer 
Table 3. Contraindications to thrombolysis in PE
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  Thrombolytic treatment is indicated (recommendation 
IIB) in selected patients with sub-massive PE/intermediate 
risk who have evidence of RHD echocardiographically and 
by  biomarkers  (BNP  or  NTproBNP),  myocardial  damage 
shown by increased levels of troponin I or T [5, 6] and not 
absolute contraindications to thrombolysis (Table 3). 
 Intravenous UFH should be reserved in patients with 
sub-massive PE/intermediate risk where there are contrain-
dications to thrombolysis. A bolus of IV UFH (in the vast 
majority of cases are made 5000 IU IV bolus, in elderly 
patients might be prudent a bolus of 3000 IU) followed by 
continuous infusion of UFH with infusion pump or syringe 
pump in a dose would lead to an increase of aPTT (time of 
activated partial thromboplastin) of 1.5 - 2.5 times the nor-
mal value, monitored by the aPTT nomograms [5, 6]. 
  In patients with non-massive/low-risk PE, the subcuta-
neous LMWH or fondaparinux at anticoagulant dose are rec-
ommended (example enoxaparin 100 IU/kg twice daily, 5 mg 
fondaparinux if weight < 50 Kg, 7.5 mg if weight between 
50 and 100 kg, 10 mg if weight > 100 kg in single dose). 
LMWH should be avoided in patients with renal failure and/
or severe obesity; in the first situation the choice is UFH, in 
obese patients the choice is subcutaneous fondaparinux at 
dosage of 10 mg/day. LMWH should be continued for the 
first 3 - 6 months for prevention of secondary venous throm-
boembolism in patients with cancer. Fondaparinux is further 
indication in patients with heparin induced thrombocytope-
nia. The intravenous UFH, LMWH and fondaparinux should 
be administered at least for five consecutive days, unless 
complications occurring, overlapping vitamin K antagonists 
(VKA) [5,6]. 
  VKA should be started in the same day of heparins 
or fondapariunx, overlapping it, with the aim of achieving a 
therapeutic range to maintain the value of  INR (Internation-
al Normalized Ratio) in the range 2 - 3 (target 2.5) in most 
patients. Heparins or fondaparinux should be discontinued 
when the value of INR is included in the therapeutic range 
for at least two consecutive days [5, 6]. 
  The indication for the positioning of vena cava filters 
are limited to situations where VKA are absolutely contrain-
dicated or VKA should be discontinued for the appearance of 
complications, or if PE has occurred in patients under VKA 
well conducted (INR in the therapeutic range). Vena cava 
filter could find indication in patients undergoing pulmo-
nary embolectomy or thromboendoarterectomy for chronic 
thromboembolic pulmonary hypertension [5, 6]. 
 Surgical or mechanical embolectomy is indicated in pa-
tients with massive/high risk PE, where there are absolute 
contraindications  to  thrombolysis,  or  this  was  ineffective 
after documentation of pulmonary thrombus through trans-
esophageal  echocardiogram  or  pulmonary  arteriography. 
Pulmonary thromboendoarterectomy is indicated in chronic 
tromboembolic pulmonary hypertension [5, 6]. 
 
Conclusions 
  PE is a common disease in clinical practice, burdened 
by  high  morbidity  and  mortality  especially  if  combined 
with  hemodynamic  instability.  Modern  guidelines  based 
on the risk estimate according to clinical and instrumental 
indicators  and  biomarkers  can  customize  treatment  with 
a  good  chance  of  success,  with  minimum  complications. 
The most important news on treatment is the possibility of 
thrombolysis in selected normotensive patients with echo-
cardiographic  and  laboratory  findings  which  are  at  high 
risk of adverse prognosis. This strategy will be evaluated 
in prospective clinical multicenter intervention trials which 
will  determine  their  effectiveness.  The  current  trial  un-
dergoing is an important European trial  (PEITHO Study) 
whose  results  are  expected  in  the  coming  years  and  that 
will give important answers to the previous question [30]. 
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